Invalid Symbol

Stock Research for RGDO

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


RGDO Stock Chart & Research Data

The RGDO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RGDO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


RGDO Due diligence Resources & Stock Charts

The RGDO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RGDO Detailed Price Forecast - CNN Money CNN View RGDO Detailed Summary - Google Finance
Yahoo View RGDO Detailed Summary - Yahoo! Finance Zacks View RGDO Stock Research & Analysis -

Stock Analysis

TradeIdeas View RGDO Trends & Analysis - Trade-Ideas Barrons View RGDO Major Holders - Barrons
NASDAQ View RGDO Call Transcripts - NASDAQ Seeking View RGDO Breaking News & Analysis - Seeking Alpha
Spotlight View RGDO Annual Report - OTC Report View RGDO OTC Short Report -
TradeKing View RGDO Fundamentals - TradeKing Charts View RGDO SEC Filings - Bar Chart
WSJ View Historical Prices for RGDO - The WSJ Morningstar View Performance/Total Return for RGDO - Morningstar
MarketWatch View the Analyst Estimates for RGDO - MarketWatch CNBC View the Earnings History for RGDO - CNBC
StockMarketWatch View the RGDO Earnings - StockMarketWatch MacroAxis View RGDO Buy or Sell Recommendations - MacroAxis
Bullish View the RGDO Bullish Patterns - American Bulls Short Pains View RGDO Short Pain Metrics -

Social Media Mentions

StockTwits View RGDO Stock Mentions - StockTwits PennyStocks View RGDO Stock Mentions - PennyStockTweets
Twitter View RGDO Stock Mentions - Twitter Invest Hub View RGDO Investment Forum News - Investor Hub
Yahoo View RGDO Stock Mentions - Yahoo! Message Board Seeking Alpha View RGDO Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for RGDO - Insider Cow View Insider Transactions for RGDO - Insider Cow
CNBC View RGDO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RGDO - OTC Markets
Yahoo View Insider Transactions for RGDO - Yahoo! Finance NASDAQ View Institutional Holdings for RGDO - NASDAQ

Stock Charts

FinViz View RGDO Stock Insight & Charts - StockCharts View RGDO Investment Charts -
BarChart View RGDO Stock Overview & Charts - BarChart Trading View View RGDO User Generated Charts - Trading View

Latest Financial News for RGDO

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Reviewing Tobira Development (TBRA) and CymaBay Therapeutics (CBAY)
The Ledger Gazette - Feb 19, 2018
CymaBay Therapeutics is trading at a lower price-to-earnings ratio than Tobira Development, indicating that it is currently the more affordable of the two stocks.

Allergan could pay up to a 1800% premium to acquire a tiny pharmaceutical company
Business Insider - Sep 20, 2016
"Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial ...
Tobira Therapeutics Up 760% Following Allergan Buyout, Liver Drug A Key Focus - Benzinga
Why Tobira Therapeutics Inc Was an Overnight Octuple - Motley Fool

Tobira Development (TBRA) vs. CymaBay Therapeutics (CBAY) Head to Head Survey
StockNewsTimes - Feb 16, 2018
6.2% of Tobira Development shares are held by company insiders. Comparatively, 15.1% of CymaBay Therapeutics shares are held by company insiders.

Tobira Therapeutics: A Worthy Contender In The NASH Space
Seeking Alpha - Dec 17, 2015
Prior to initiating studies on NASH, Tobira was testing CVC in HIV. In March 2013, it was reported to have a positive Phase 2b trial for CVC in the treatment of HIV Infection.

Enter a stock symbol to view the stock details.